CMPS COMPASS Pathways Plc - American Depository Shares
NASDAQ · Biotechnology · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Aug 5, 2026
$11.90
· of 52w range
· above low
· to high
$4.8852w low
$15.8752w high
Market Cap (MRQ)
$1.62B
P/E
-3.9
EPS
$-3.08
your badges
52W Range
$5–$16
Analyst Rating
BUY
Price Target
$24
P/E
-3.9
ROE
-524.8%
Net Profit Margin
·
Your badge strip is empty — pin a metric anywhere on this page.
CMPS Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$11.90
Market Cap (MRQ)
$1.62B
P/E
-3.9
EPS
$-3.08
ROE
-524.8%
Debt/Equity (MRQ)
0.6
52W Range
$5–$16
CMPS Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
About COMPASS Pathways Plc - American Depository Shares Company overview from Wikipedia
Compass Pathways, or COMPASS Pathways, is a British pharmaceutical company developing psychedelics as potential medicines. Its main drug candidate, psilocybin (COMP360), has completed phase 3 clinical trials for treatment-resistant depression. The results showed clear benefit to participants as measured on the MADRS depression rating scale. This candidate has received breakthrough therapy status from the U.S. Food and Drug Administration (FDA). It is the most advanced psychedelic drug candidate in development besides Lykos Therapeutics's midomafetamine (MDMA).
Compass Pathways is the largest company in the psychedelic medicine industry and, in 2020, was the first psychedelic medicine company to be listed on the NASDAQ. It has faced criticism for patenting psychedelic drugs and even certain psilocybin mushroom species. In October 2024, after the FDA rejected Lykos Therapeutics's MDMA for post-traumatic stress disorder (PTSD) New Drug Application (NDA), Compass Pathways said that it would lay off 30% of its workforce and narrow its research focus.
Compass Pathways has entered partnerships with several independent psychedelic academic scientists, including Jason Wallach, Hamilton Morris, and Adam Halberstadt among others, to develop novel psychedelic drugs for potential medical use. Wallach's lab is said to have sought patents for over 200 novel compounds as of May 2024.
Compass Pathways switched from being a nonprofit organization to a for-profit company in 2016. The pharmaceutical company has been backed and funded by a number of tech entrepreneurs such as Peter Thiel. The media outlet Sifted remarks that the biotech billionaire Christian Angermayer was instrumental in the founding of Compass Pathways."
Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗
sectorHealthcare
industryBiotechnology
employees156
countryGB
10-Year Performance Revenue, net income, margins and EPS trends
EPS$-3.082019-12-31 → 2025-12-31
Free Cash Flow·2021-12-31 → 2024-12-31
Valuation & Ratios
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | CMPS | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E | -3.95Y avg ≈-4.7 | ≈-4.7 | · | · | |
| P/B (MRQ) | 19.1 | · | 6.8 | Overvalued | |
| EV / EBITDA | -5.7 | · | · | · | |
| Price / Cash Flow | -7.3 | · | · | · | |
| Price / Tangible Book | 2.9 | · | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | CMPS | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| ROA | -135.8%5Y avg ≈-62.9% | ≈-62.9% | -5.4% | Weak | |
| ROE | -524.8%5Y avg ≈-147.3% | ≈-147.3% | -9.2% | Weak | |
| ROIC | 836.7%5Y avg ≈117.6% | ≈117.6% | -17.1% | Top tier |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | CMPS | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Debt / Equity (MRQ) | 0.6 | · | · | · | |
| Current Ratio (MRQ) | 1.35Y avg ≈10.4 | ≈10.4 | 4.5 | Low liquidity | |
| Quick Ratio | 0.65Y avg ≈8.8 | ≈8.8 | 3.2 | Low liquidity | |
| Long-Term Debt / Equity (MRQ) | 0.6 | · | · | · |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
-103.4%
Next Report
Nov 02, 2026
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Jul 29, 2026 | $-1.88 | $-0.41 | -364.1% |
| March 31, 2026 | May 13, 2026 | $-0.30 | $-0.39 | 22.2% |
| Dec. 31, 2025 | $-1.00 | $-0.40 | -148.6% | |
| Sept. 30, 2025 | $-1.44 | $-0.40 | -262.0% | |
| June 30, 2025 | $-0.41 | $-0.44 | 6.1% | |
| March 31, 2025 | $-0.38 | $-0.48 | 20.4% | |
| Dec. 31, 2024 | $-0.63 | $-0.64 | 2.3% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| R&D Expense | $118M | $119M | $88M | $65M | $44M | $23M | |
| SG&A Expense | $61M | $59M | $49M | $45M | $39M | $28M | |
| Operating Expenses | $179M | $178M | $137M | $110M | $83M | $51M | |
| Operating Income | $-179M | $-178M | $-137M | $-110M | $-83M | $-51M | |
| Interest Expense | · | · | $2M | $0 | $0 | · | |
| Interest Income | $7M | $8M | $5M | · | · | · | |
| Other Non-op | $1M | $823.0K | $255.0K | $19M | $12M | $-9M | |
| Pretax Income | $-290M | $-154M | $-118M | $-91M | $-72M | $-60M | |
| Income Tax | $-2M | $2M | $780.0K | $408.0K | $199.0K | $32.0K | |
| Net Income | $-288M | $-155M | $-118M | $-92M | $-72M | $-60M | |
| EPS (Basic) | $-3.08 | $-2.30 | $-2.32 | $-2.16 | $-1.79 | $-3.55 | |
| EPS (Diluted) | $-3.08 | $-2.30 | $-2.32 | $-2.16 | $-1.79 | $-3.55 | |
| Shares (Basic) | 93,504,836 | 67,482,902 | 51,028,024 | 42,436,292 | 39,997,587 | 16,991,664 | |
| Shares (Diluted) | 93,504,836 | 67,482,902 | 51,028,024 | 42,436,292 | 39,997,587 | 16,991,664 | |
| EBITDA | $-179M | $-178M | $-137M | $-110M | $-83M | · |
Balance Sheet
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $150M | $165M | $220M | $143M | $273M | $190M | |
| Prepaid Expense | $42M | $36M | $41M | $48M | $22M | $12M | |
| Other Current Assets | $6M | $4M | $2M | $1M | $1M | $509.0K | |
| Current Assets | $191M | $201M | $261M | $192M | $295M | $202M | |
| PP&E (Net) | · | $189.0K | $423.0K | $617.0K | $398.0K | $245.0K | |
| PP&E (Gross) | · | · | · | $1M | $756.0K | $433.0K | |
| Accum. Depreciation | · | · | · | $530.0K | $358.0K | $188.0K | |
| Other Non-current Assets | $12M | $7M | $7M | $1M | $213.0K | $57.0K | |
| Total Assets | $210M | $214M | $276M | $197M | $301M | $203M | |
| Accounts Payable | $15M | $12M | $6M | $5M | $3M | $3M | |
| Current Liabilities | $248M | $34M | $20M | $16M | $15M | $7M | |
| Capital Leases | $1M | $303.0K | $2M | $418.0K | $1M | · | |
| Total Liabilities | $263M | $59M | $50M | $16M | $16M | $7M | |
| Long-term Debt | $32M | $30M | $29M | $0 | · | · | |
| Total Debt | $32M | $30M | · | · | · | · | |
| Common Stock | $973.0K | $702.0K | $635.0K | · | · | · | |
| Paid-in Capital | $784M | $705M | $622M | $459M | $445M | $279M | |
| Retained Earnings | $-823M | $-535M | $-380M | $-261M | $-170M | $-98M | |
| AOCI | $-15M | $-16M | $-17M | $-17M | $9M | $15M | |
| Stockholders' Equity | $-53M | $155M | $226M | $181M | $284M | $197M | |
| Liabilities + Equity | $210M | $214M | $276M | $197M | $301M | $203M | |
| Shares Outstanding | 96,085,785 | 68,552,215 | 61,943,471 | · | · | · |
Cash Flow
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| D&A | · | · | $242.0K | $330.0K | $175.0K | $112.0K | |
| Stock-based Comp | $14M | $20M | $17M | $13M | $9M | $18M | |
| Deferred Tax | $22.0K | $-437.0K | $-1M | $-1M | $-545.0K | $-221.0K | |
| Other Non-cash | · | · | $5M | $-26M | $-4M | · | |
| Operating Cash Flow | $-157M | $-119M | $-97M | $-105M | $-68M | $-41M | |
| CapEx | · | $0 | $66.0K | $596.0K | $334.0K | $131.0K | |
| Investing Cash Flow | · | $0 | $-64.0K | $-596.0K | $-334.0K | $-628.0K | |
| Debt Issued | · | $0 | $30M | $0 | $0 | · | |
| Net Debt Issued | · | $0 | $30M | · | · | · | |
| Stock Issued | $140M | $26M | $145M | $440.0K | $155M | $0 | |
| Net Stock Activity | $140M | $26M | $145M | $440.0K | $155M | · | |
| Financing Cash Flow | $141M | $64M | $174M | $1M | $157M | $194M | |
| Net Change in Cash | $-15M | $-55M | $77M | $-130M | $83M | $165M | |
| Taxes Paid | $755.0K | · | · | · | · | · | |
| Free Cash Flow | · | $-119M | $-97M | $-106M | $-68M | · | |
| Levered FCF | · | · | $-100M | · | · | · |
Profitability
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| ROA | -135.8% | -63.4% | -50.1% | -36.7% | -28.4% | · | |
| ROE | -524.8% | -89.2% | -49.5% | -48.7% | -24.3% | · | |
| ROIC | 836.7% | -97.4% | -61.1% | -61.2% | -29.3% | · |
Liquidity & Solvency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 0.8 | 5.9 | 13.3 | 12.3 | 19.5 | · | |
| Quick Ratio | 0.6 | 4.9 | 11.2 | 9.2 | 18.1 | · | |
| Debt / Equity | -0.6 | 0.2 | · | · | · | · | |
| LT Debt / Equity | -0.3 | 0.2 | · | · | · | · | |
| Interest Coverage | · | · | -62.1 | · | · | · |
Per Share
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Book Value / Share | $-0.55 | $2.26 | · | · | · | · | |
| Cash Flow / Share | $-1.68 | $-1.77 | $-1.91 | $-2.48 | $-1.69 | · | |
| Cash / Share | $1.56 | $2.41 | · | · | · | · | |
| EPS (TTM) | $-3.08 | $-2.30 | $-2.32 | $-2.16 | $-1.79 | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Net Income TTM | $-288M | $-155M | $-118M | $-92M | $-72M | · | |
| Market Cap | $663M | $259M | · | · | · | · | |
| Enterprise Value | $545M | $124M | · | · | · | · | |
| P/E | -2.2 | -1.6 | -3.8 | -3.7 | -12.3 | · | |
| P/B | -12.5 | 1.7 | · | · | · | · | |
| P / Tangible Book | · | 1.7 | · | · | · | · | |
| P / Cash Flow | -4.2 | -2.2 | · | · | · | · | |
| P / FCF | · | -2.2 | · | · | · | · | |
| EV / EBITDA | -3.0 | -0.7 | · | · | · | · | |
| EV / FCF | · | -1.0 | · | · | · | · | |
| Earnings Yield | -44.6% | -60.9% | -26.5% | -26.9% | -8.1% | · |
Income Statement
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $29M | $26M | $30M | $27M | $30M | $31M | $32M | $33M | $29M | $25M | $27M | $22M | $20M | $19M | $20M | $14M | |
| SG&A Expense | $23M | $16M | $16M | $13M | $13M | $19M | $16M | $15M | $14M | $14M | $11M | $13M | $13M | $13M | $12M | $12M | |
| Operating Expenses | $52M | $43M | $46M | $41M | $43M | $50M | $48M | $48M | $43M | $39M | $38M | $34M | $33M | $32M | $32M | $26M | |
| Operating Income | $-52M | $-43M | $-46M | $-41M | $-43M | $-50M | $-48M | $-48M | $-43M | $-39M | $-38M | $-34M | $-33M | $-32M | $-32M | $-26M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $1M | · | $1M | · | $0 | $0 | $0 | |
| Interest Income | $4M | $2M | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $638.0K | · | · | · | |
| Other Non-op | $546.0K | $484.0K | $370.0K | $383.0K | $-176.0K | $803.0K | $337.0K | $191.0K | $167.0K | $128.0K | $-8M | $112.0K | $-11.0K | $8M | $1M | $7M | |
| Pretax Income | $-253M | $91M | $-97M | $-138M | $-38M | $-18M | $-42M | $-38M | $-38M | $-35M | $-32M | $-33M | $-28M | $-24M | $-31M | $-18M | |
| Income Tax | $331.0K | $-11.0K | $-3M | $-230.0K | $137.0K | $354.0K | $1M | $173.0K | $176.0K | $222.0K | $394.0K | $62.0K | $194.0K | $130.0K | $92.0K | $120.0K | |
| Net Income | $-254M | $91M | $-94M | $-138M | $-38M | $-18M | $-43M | $-39M | $-38M | $-35M | $-33M | $-33M | $-28M | $-24M | $-31M | $-18M | |
| EPS (Basic) | $-1.88 | $0.71 | $-1.03 | $-1.44 | $-0.41 | $-0.20 | $-0.63 | $-0.56 | $-0.56 | $-0.55 | $618.92 | $-0.67 | $-620.00 | $-0.57 | $-0.73 | $-0.43 | |
| EPS (Diluted) | $-1.88 | $-0.30 | $-0.99 | $-1.44 | $-0.41 | $-0.24 | $-0.63 | $-0.56 | $-0.56 | $-0.55 | $618.92 | $-0.67 | $-620.00 | $-0.57 | $-0.73 | $-0.43 | |
| Shares (Basic) | 135,039,810 | 110,064,581 | · | 95,337,993 | 93,341,594 | 89,192,252 | · | 68,395,343 | 68,371,139 | 64,222,178 | · | 49,633,104 | 45,565,991 | 42,725,863 | · | 42,525,855 | |
| Shares (Diluted) | 135,039,810 | 130,266,693 | · | 95,337,993 | 93,341,594 | 98,641,623 | · | 68,395,343 | 68,371,139 | 64,222,178 | · | 49,633,104 | 45,565,991 | 42,725,863 | · | 42,525,855 | |
| EBITDA | $-52M | $-43M | · | $-41M | $-43M | $-50M | · | $-48M | $-43M | $-39M | · | $-34M | $-33M | $-32M | · | $-25M |
Balance Sheet
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $433M | $466M | $150M | $186M | $222M | $260M | $165M | $207M | $229M | $263M | $220M | $248M | $148M | $117M | $143M | $173M | |
| Prepaid Expense | $42M | $44M | $42M | $56M | $54M | $45M | $36M | $26M | $36M | $31M | $41M | $36M | $45M | $50M | $48M | $45M | |
| Other Current Assets | $8M | $7M | $6M | $3M | $2M | $2M | $4M | $2M | $3M | $2M | $2M | $2M | $2M | $1M | $1M | $1M | |
| Current Assets | $476M | $511M | $191M | $242M | $276M | $305M | $201M | $234M | $265M | $296M | $261M | $285M | $194M | $168M | $192M | $218M | |
| PP&E (Net) | · | · | · | · | · | · | · | · | · | $359.0K | $423.0K | $309.0K | $482.0K | $612.0K | $617.0K | $555.0K | |
| PP&E (Gross) | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $950.0K | |
| Accum. Depreciation | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $395.0K | |
| Other Non-current Assets | $20M | $14M | $12M | $5M | $9M | $8M | $7M | $7M | $6M | $6M | $7M | $6M | $7M | $212.0K | $1M | $299.0K | |
| Total Assets | $505M | $532M | $210M | $256M | $294M | $319M | $214M | $247M | $279M | $309M | $276M | $299M | $210M | $173M | $197M | $225M | |
| Accounts Payable | $12M | $11M | $15M | $5M | $11M | $9M | $12M | $8M | $8M | $9M | $6M | $4M | $2M | $4M | $5M | $20M | |
| Current Liabilities | $367M | $154M | $248M | $197M | $31M | $30M | $34M | $26M | $22M | $19M | $20M | $15M | $13M | $11M | $16M | $30M | |
| Capital Leases | $2M | $779.0K | $1M | $2M | $2M | $259.0K | $303.0K | $459.0K | $799.0K | $1M | $2M | $2M | $3M | $412.0K | $418.0K | $425.0K | |
| Total Liabilities | $420M | $205M | $263M | $218M | $131M | $124M | $59M | $54M | $52M | $50M | $50M | $46M | $43M | $12M | $16M | $30M | |
| Long-term Debt | $51M | $50M | $32M | $31M | $31M | $31M | $30M | $30M | $29M | $29M | $29M | $28M | $28M | · | $0 | · | |
| Total Debt | $51M | $50M | · | $31M | $31M | $31M | · | $28M | · | · | · | · | · | · | · | · | |
| Common Stock | $1M | $1M | $973.0K | $973.0K | $946.0K | $938.0K | $702.0K | $699.0K | $699.0K | $699.0K | $635.0K | · | · | · | · | · | |
| Paid-in Capital | $1.08B | $1.07B | $784M | $781M | $767M | $763M | $705M | $700M | $695M | $690M | $622M | $617M | $496M | $464M | $459M | $455M | |
| Retained Earnings | $-985M | $-731M | $-823M | $-729M | $-591M | $-553M | $-535M | $-491M | $-453M | $-415M | $-380M | $-347M | $-314M | $-285M | $-261M | $-230M | |
| AOCI | $-15M | $-15M | $-15M | $-15M | $-15M | $-16M | $-16M | $-17M | $-17M | $-17M | $-17M | $-17M | $-17M | $-17M | $-17M | $-31M | |
| Stockholders' Equity | $85M | $327M | $-53M | $38M | $163M | $195M | $155M | $193M | $226M | $259M | $226M | $253M | $166M | $162M | $181M | $195M | |
| Liabilities + Equity | $505M | $532M | $210M | $256M | $294M | $319M | $214M | $247M | $279M | $309M | $276M | $299M | $210M | $173M | $197M | $225M | |
| Shares Outstanding | 135,722,306 | 134,923,295 | 96,085,785 | 96,002,044 | 93,586,348 | 92,848,326 | 68,552,215 | 68,409,068 | 68,387,469 | 68,342,534 | 61,943,471 | · | · | · | · | · |
Cash Flow
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | $59.0K | $63.0K | $61.0K | · | $186.0K | $110.0K | $48.0K | $76.0K | $100.0K | |
| Stock-based Comp | $4M | $3M | $3M | $3M | $4M | $4M | $4M | $5M | $5M | $5M | $4M | $4M | $5M | $4M | $3M | $4M | |
| Other Non-cash | · | · | · | · | · | · | · | · | · | $9M | · | · | · | $-8M | · | · | |
| Operating Cash Flow | $-40M | $-48M | $-38M | $-35M | $-39M | $-46M | $-42M | $-22M | $-34M | $-21M | $-28M | $-17M | $-25M | $-28M | $-45M | $-19M | |
| CapEx | · | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $18.0K | $19.0K | $29.0K | $107.0K | $-5.0K | |
| Investing Cash Flow | · | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $-18.0K | $-17.0K | $-29.0K | $-107.0K | $5.0K | |
| Debt Issued | $0 | $19M | · | · | $0 | $0 | · | $0 | · | · | $0 | $0 | · | · | $0 | $0 | |
| Net Debt Issued | · | $19M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Stock Issued | · | $141M | $0 | $0 | $0 | $140M | $0 | $0 | $0 | $26M | $-41.0K | $117M | $27M | $1M | $440.0K | $0 | |
| Net Stock Activity | · | $141M | · | · | · | $140M | · | · | · | $26M | · | · | · | $1M | · | · | |
| Financing Cash Flow | $8M | $362M | $187.0K | $0 | $166.0K | $140M | $155.0K | $-53.0K | $210.0K | $64M | $41.0K | $117M | $56M | $1M | $639.0K | $-1.0K | |
| Net Change in Cash | $-33M | $316M | $-36M | $-36M | $-38M | $95M | $-42M | $-22M | $-34M | $43M | $-28M | $100M | $31M | $-26M | $-30M | $-34M | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | $-21M | · | · | · | $-28M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $-22M | · | · | · | · | · | · |
Profitability
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROA | -63.6% | 21.4% | · | -54.8% | -13.4% | -5.7% | · | -14.1% | -15.6% | -14.6% | · | -12.8% | -12.6% | -10.9% | · | -16.4% | |
| ROE | -205.4% | 34.9% | · | -119.4% | -19.8% | -7.9% | · | -17.2% | -19.4% | -16.7% | · | -14.9% | -14.5% | -11.5% | · | -18.9% | |
| ROIC | -38.8% | -11.4% | · | -58.8% | -22.3% | -22.4% | · | -21.8% | -19.2% | -15.0% | · | -13.5% | -19.8% | -19.8% | · | -13.2% |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.3 | 3.3 | · | 1.2 | 8.8 | 10.2 | · | 8.9 | 12.0 | 15.2 | · | 18.6 | 15.2 | 14.9 | · | 7.4 | |
| Quick Ratio | 1.2 | 3.0 | · | 0.9 | 7.1 | 8.7 | · | 7.9 | 10.4 | 13.5 | · | 16.2 | 11.6 | 10.4 | · | 5.9 | |
| Debt / Equity | 0.6 | 0.2 | · | 0.8 | 0.2 | 0.2 | · | 0.1 | · | · | · | · | · | · | · | · | |
| LT Debt / Equity | 0.6 | 0.2 | · | 0.5 | 0.1 | 0.1 | · | 0.1 | · | · | · | · | · | · | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | -35.1 | · | -31.5 | · | · | · | · |
Per Share
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.62 | $2.42 | · | $0.39 | $1.74 | $2.11 | · | $2.82 | $3.31 | $3.79 | · | · | · | · | · | · | |
| Cash Flow / Share | · | $-0.37 | · | · | · | $-0.46 | · | · | · | $-0.32 | · | · | · | $-0.65 | · | · | |
| Cash / Share | $3.19 | $3.45 | · | $1.94 | $2.37 | $2.80 | · | $3.03 | $3.34 | $3.85 | · | · | · | · | · | · | |
| EPS (TTM) | $-4.61 | $-3.14 | · | $-2.72 | $-1.84 | $-1.99 | · | $617.25 | $617.14 | $-2.30 | · | $-621.97 | $-621.73 | $-2.23 | · | $-2.05 |
Valuation (TTM)
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-394M | $-179M | · | $-237M | $-138M | $-138M | · | $-144M | $-139M | $-129M | · | $-117M | $-102M | $-95M | · | $-86M | |
| Market Cap | $1.92B | $746M | · | $550M | $262M | $266M | · | $431M | $413M | $569M | · | · | · | · | · | · | |
| Enterprise Value | $1.54B | $331M | · | $395M | $71M | $36M | · | $252M | · | · | · | · | · | · | · | · | |
| P/E | -3.1 | -1.8 | · | -2.1 | -1.5 | -1.4 | · | 0.0 | 0.0 | -3.6 | · | -0.0 | -0.0 | -4.5 | · | -5.2 | |
| P/B | 22.7 | 2.3 | · | 14.6 | 1.6 | 1.4 | · | 2.2 | 1.8 | 2.2 | · | · | · | · | · | · | |
| P / Tangible Book | 22.7 | 2.3 | · | 14.6 | 1.6 | 1.4 | · | 2.2 | 1.8 | 2.2 | · | · | · | · | · | · | |
| P / Cash Flow | · | -15.6 | · | · | · | -5.8 | · | · | · | -27.3 | · | · | · | · | · | · | |
| Earnings Yield | -32.6% | -56.8% | · | -47.5% | -65.7% | -69.6% | · | 9797.6% | 10217.5% | -27.6% | · | -8405.0% | -7508.8% | -22.5% | · | -19.1% |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Net Income | $-288M | $-155M | $-118M | $-92M | $-72M |
| Diluted EPS | $-3.08 | $-2.30 | $-2.32 | $-2.16 | $-1.79 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Debt / Equity | -0.6 | 0.2 | · | · | · |
| Current Ratio | 0.8 | 5.9 | 13.3 | 12.3 | 19.5 |
| Quick Ratio | 0.6 | 4.9 | 11.2 | 9.2 | 18.1 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Free Cash Flow | · | $-119M | $-97M | $-106M | $-68M |
Institutional owners (13F) 248 filers · $1.4B total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Holders
248
Value held
$1.4B
New positions
65
Exited positions
30
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 65 (+5 vs prior Q) | 30 (+7 vs prior Q) | 78 (+4 vs prior Q) | 54 (+25 vs prior Q) | -1.1M |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| Deep Track Capital, LP | $172,085,168 | 12,161,496 | 12.70% | Shares |
| RTW INVESTMENTS, LP | $151,418,782 | 10,700,974 | 11.18% | Shares |
| BIT Capital GmbH | $89,835,478 | 6,348,797 | 6.63% | Shares |
| TANG CAPITAL MANAGEMENT LLC | $70,750,000 | 5,000,000 | 5.22% | Shares |
| TWO SIGMA INVESTMENTS, LP | $63,257,363 | 4,470,485 | 4.67% | Shares |
| MARSHALL WACE, LLP | $61,250,852 | 4,328,682 | 4.52% | Shares |
| ARK Investment Management LLC | $48,845,310 | 3,451,965 | 3.61% | Shares |
| Point72 Asset Management, L.P. | $37,085,424 | 2,620,878 | 2.74% | Shares |
| Logos Global Management LP | $31,837,500 | 2,250,000 | 2.35% | Shares |
| Eagle Health Investments LP | $29,155,042 | 2,060,427 | 2.15% | Shares |
| BANK OF AMERICA CORP /DE/ | $28,573,774 | 2,019,348 | 2.11% | Shares |
| DAFNA Capital Management LLC | $28,469,121 | 2,011,952 | 2.10% | Shares |
| Caption Management, LLC | $27,544,390 | 1,946,600 | 2.03% | Call option |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $26,855,285 | 1,897,900 | 1.98% | Call option |
| NEXTBio Capital Management LP | $25,126,990 | 1,775,759 | 1.85% | Shares |
| UBS Group AG | $20,976,951 | 1,482,470 | 1.55% | Shares |
| Aisling Capital Management LP | $20,267,554 | 1,432,336 | 1.50% | Shares |
| RENAISSANCE TECHNOLOGIES LLC | $20,261,229 | 1,431,889 | 1.50% | Shares |
| Candriam S.C.A. | $18,013,686 | 1,274,278 | 1.33% | Shares |
| Woodline Partners LP | $15,366,957 | 1,086,004 | 1.13% | Shares |
| CITADEL ADVISORS LLC | $14,219,052 | 1,004,880 | 1.05% | Shares |
| Jefferies Financial Group Inc. | $14,070,661 | 994,393 | 1.04% | Shares |
| BlackRock, Inc. | $13,094,283 | 925,391 | 0.97% | Shares |
| Trexquant Investment LP | $12,171,236 | 860,158 | 0.90% | Shares |
| Kalehua Capital Management LLC | $11,598,642 | 819,692 | 0.86% | Shares |
| MILLENNIUM MANAGEMENT LLC | $10,909,466 | 770,987 | 0.81% | Shares |
| Caption Management, LLC | $10,699,041 | 756,116 | 0.79% | Shares |
| Eversept Partners, LP | $9,520,474 | 672,825 | 0.70% | Shares |
| MORGAN STANLEY | $8,417,922 | 594,906 | 0.62% | Shares |
| Propel Bio Management, LLC | $8,109,167 | 573,086 | 0.60% | Shares |
| Creek Drive Management Group LLC | $8,093,800 | 572,000 | 0.60% | Shares |
| Occam Crest Management LP | $7,739,000 | 710,000 | 0.57% | Shares |
| CITADEL ADVISORS LLC | $7,567,420 | 534,800 | 0.56% | Call option |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $7,140,090 | 504,600 | 0.53% | Put option |
| SILVERARC CAPITAL MANAGEMENT, LLC | $7,122,855 | 503,382 | 0.53% | Shares |
| JANE STREET GROUP, LLC | $7,102,310 | 501,930 | 0.52% | Shares |
| Qube Research & Technologies Ltd | $7,070,415 | 499,676 | 0.52% | Shares |
| Walleye Capital LLC | $6,893,385 | 487,165 | 0.51% | Shares |
| Ensign Peak Advisors, Inc | $6,716,340 | 474,653 | 0.50% | Shares |
| Blue Owl Capital Holdings LP | $6,367,500 | 450,000 | 0.47% | Shares |
| AdvisorShares Investments LLC | $5,962,060 | 421,347 | 0.44% | Shares |
| TWO SIGMA ADVISERS, LP | $5,909,850 | 856,500 | 0.44% | Shares |
| GOLDMAN SACHS GROUP INC | $5,540,956 | 391,587 | 0.41% | Shares |
| LANDSCAPE CAPITAL MANAGEMENT, L.L.C. | $5,438,567 | 384,351 | 0.40% | Shares |
| HighVista Strategies LLC | $5,251,349 | 371,120 | 0.39% | Shares |
| Legal & General Group Plc | $4,700,154 | 332,206 | 0.35% | Shares |
| Sumitomo Mitsui Trust Group, Inc. | $4,573,407 | 323,209 | 0.34% | Shares |
| Amova Asset Management Americas, Inc. | $4,517,334 | 319,472 | 0.33% | Shares |
| Squadron Capital Management LLC | $4,315,750 | 305,000 | 0.32% | Call option |
| Affinity Asset Advisors, LLC | $4,261,739 | 301,183 | 0.31% | Shares |
Activists & 5%+ owners 1 position
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| AtaiBeckley Inc. | Feb. 17, 2026 | 4.96% | Amendment | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 19 insiders · 6 officers · 10 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Kabir Nath | Chief Executive Officer | Aug. 3, 2026 F | 361,028 | 0 | 0 | $0 |
| Teri Loxam | Chief Financial Officer | March 26, 2026 A | 152,002 | 0 | 0 | $0 |
| Mary-Rose Hughes | Interim CFO | Feb. 1, 2024 A | · | 0 | 0 | $0 |
| Michael Falvey | Chief Financial Officer | Feb. 2, 2023 A | 22,500 | 0 | 0 | $0 |
| Guy Goodwin | Chief Medical Officer | March 26, 2026 A | 8,000 | 0 | 0 | $0 |
| Matthew A Owens | General Counsel & CLO | Feb. 1, 2024 A | 43,340 | 0 | 0 | $0 |
| Robert Mcquade | Director | May 27, 2026 A | · | 0 | 0 | $0 |
| Kathleen Tregoning | Director | May 27, 2026 A | · | 0 | 0 | $0 |
| Daphne Karydas | Director | May 27, 2026 A | · | 0 | 0 | $0 |
| Justin D. Gover | Director | May 27, 2026 A | · | 0 | 0 | $0 |
| David Y Norton | Director | May 27, 2026 A | 20,356 | 0 | 0 | $0 |
| Wayne Joseph Riley | Director | May 27, 2026 A | · | 0 | 0 | $0 |
| Thomas Lonngren | Director | June 12, 2025 A | · | 0 | 0 | $0 |
| Annalisa Jenkins | Director | June 12, 2025 A | 19,480 | 0 | 0 | $0 |
| Linda Mcgoldrick | Director | June 12, 2025 A | · | 0 | 0 | $0 |
| Ekaterina Malievskaia | 10% owner | Oct. 24, 2024 S | 3,155,122 | 0 | 0 | $0 |
| George Jay Goldsmith | 10% owner | Oct. 24, 2024 S | 3,152,848 | 0 | 0 | $0 |
| Gino Santini | · | May 27, 2026 A | · | 0 | 0 | $0 |
| Jeffrey M Jonas | · | May 27, 2026 A | · | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 6 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| ARKG · ARK ETF Trust | 3.25% | 4,463,875 NS | July 31, 2026 | N-PORT |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 0.93% | 56,358 NS | July 31, 2026 | N-PORT |
| BBC · ETFis Series Trust I | 0.63% | 25,731 NS | July 31, 2026 | N-PORT |
| ESIM · Strategy Shares | 0.13% | 2,020 NS | July 31, 2026 | N-PORT |
| IBB · iShares Trust | 0.11% | 831,209 SH | Sept. 11, 2026 | Daily |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0.11% | 9,493 SH | Oct. 1, 2026 | Daily |
CMPS Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
rating · 24 analysts
BUY
Median target
$21.00
+76.5%
8 33.3%
Strong Buy
14 58.3%
Buy
2 8.3%
Hold
0 0.0%
Sell
0 0.0%
Strong Sell
12-Month Price Target
16 analysts · 2026-09-20Mean target $23.75 +99.6%
← Below all targets
Current price $11.90
Low$13.00
Mean$23.75
High$65.00
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
Latest News Recent headlines mentioning this company
FDA Grants Rolling Review and CNPV Designation to Compass Pathways (CMPS) for TRD Treatment
Yahoo Finance · 5 months ago
Trump Sends Compass Pathways Stock Soaring as He Backs Psychedelics. Should You Buy CMPS Here?
Yahoo Finance · 5 months, 1 week ago
Why Compass Pathways Stock Rocketed 40% Today
Nasdaq · 5 months, 1 week ago
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Source: SEC 10-Q filed Aug 5, 2026